Quick Answer
Evommune, Inc. reported Cash and Equivalents of $44.06 million for fiscal year 2025.
Evommune, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $44.06M | +171.1% |
| 2024 | $16.25M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $26.82M | +47.8% | +65.0% |
| December 31, 2024 | $16.25M | — | -10.4% |
| September 30, 2024 | $18.15M | — | — |
- Evommune, Inc. showed an increase of +171.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2024–2025 period, Evommune, Inc.’s cash and equivalents has grown by 171.1% (from $16.25 million to $44.06 million).
- The most recent figure is from Evommune, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: